ABSTRACT BACKGROUND Most patients with chest pain are discharged from the emergency department (ED) with the diagnosis
adverse cardiac event (MACE) within 30 days (9) . By introducing cardiac troponin T (cTnT) assays with higher sensitivity, diagnostic accuracy has improved in patients with suspected acute coronary syndrome (ACS) (1, 7, (10) (11) (12) . However, it has not been reported previously whether the clinical use of newer troponin assays has affected the MACE rate in patients discharged with the diagnosis of unspecified chest pain.
This study therefore aimed to investigate whether the implementation of high-sensitivity TnT (hsTnT) assays in Swedish hospitals resulted in reduced incidence of MACE in patients with chest pain discharged from the ED. A secondary objective was to study the risk factor profile of discharged patients in relation to their evaluation with different cTnT assays.
METHODS
This registry-based cohort study included all patients age 18 years and older who were discharged with the diagnosis "unspecified chest pain" (defined 
. Hospitals without information on the troponin assay used were excluded. All patients in the study were divided into 2 groups depending on whether they had been discharged after an initial admission at an acute short-term ward or observation unit at the emergency service or whether they were discharged directly from the ED. All patients with a reported discharge date in addition to an admission date were considered to have been admitted. Patients with only an admission date and without a record of a following hospitalization were considered to have been sent home directly from the ED.
HIGH-SENSITIVITY ASSAY USED. During the study period, the current iteration of the cTnT assay (Roche Diagnostics, Basel, Switzerland) was the only method with higher precision in use; it was implemented in 16 hospitals. For this assay, the 99th percentile for measuring cTnT among healthy controls is 14 ng/l and the lowest concentration measurable with a 10% coefficient of variation is 13 ng/l (14) . In this study, we refer to this assay with its "high sensitivity" as hsTnT. The analytical profile of conventional assays in use could be collectively termed as sensitive; these assays are referred to as "conventional." Several conventional assays were in use. The cTnT was used in 10 hospitals with a total of 16, 836 visits; for this assay, the 99th percentile among healthy controls is 0.01 mg/l and the lowest concentration measurable with a 10% coefficient of variation is 0.04 mg/l. A cardiac troponin I assay (Siemens Medical Solutions USA, Inc., Malvern, Pennsylvania) was used in 2 hospitals with a total of 3,710 visits; for this assay, the 99th percentile among healthy controls is 0.07 mg/l and the lowest concentration measurable with a 10% coefficient of variation is 0.06 mg/l. A cardiac troponin I assay (Beckman Coulter, Inc., Brea, California) assay was used in 2 hospitals with a total of 9,218 visits; for this assay, the 99th percentile among healthy controls is 0.04 mg/l and the lowest concentration measurable with a 10% coefficient of variation is 0.06 mg/l. A combination of these assays was used in 2 hospitals with a total of 4,104 visits. After exclusions, 65,696 of the original 82,922 patients remained. "Discharged after admission" denotes patients discharged after an initial admission at the emergency service and "directly discharged" denotes patients who were discharged directly from the emergency department. hsTnT ¼ high-sensitivity troponin T.
Nejatian et al. STATISTICAL ANALYSIS. Potential association between study period and continuous and categorical background variables was analyzed using 2 sample
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Student t test and chi-square test, respectively.
Chi-square test was also used in the bivariate analysis between troponin assay and the different outcomes.
To estimate odds ratios (ORs) between troponin assay and MACE, univariate and multivariate logistic regression was used.
To determine which variables to control for in the multivariate setting, we ran several univariate logistic regression models with MACE as outcome and age (using restricted cubic spline), sex, diabetes mellitus, hyperlipidemia, hypertension, obesity, previous MI, and previous heart failure as predictors. All variables but obesity were statistically significant in the univariate setting and were therefore included in the multivariate models. Because troponin assays are highly sampling-time dependent, we decided to adjust for date of ED visit in the multivariate models, regardless of statistical significance.
The statistics were calculated using SPSS Statistics, Values are mean AE SD or n (%). *Diagnosis and/or prescriptions for drugs to treat the condition.
hsTnT ¼ high-sensitivity troponin T; MI ¼ myocardial infarction.
Among admitted patients, more had cardiovascular risk factors during study period 2, but there was no difference in medical history of cardiovascular diseases ( Table 2) . A total of 199 patients (3.4%) experienced a MACE within 30 days before compared with 157 patients (7.2%) after the introduction of the hsTnT assay (p < 0.001). The individual variables in the composite endpoint MACE (MI, unplanned revascularization, or death) can be seen in Table 3 .
In contrast to the directly discharged patients, there was a significant increase in the number of MACE Tables 1 and 2) , the association between the study period (before and after the implementation of the hsTnT assay) and the MACE rate was not significant, neither among directly discharged or patients discharged after admission.
DISCUSSION
To our knowledge, this is the first study investigating whether the implementation of an hsTnT assay is associated with the incidence of MACE in chest pain patients discharged from the ED. Although the absolute risk reduction was low, patients with chest pain who were directly sent home from the ED after the reported that more at-risk patients were admitted, suitable for beneficial therapies, and that there was a significant increase in ACS, both MI and unstable angina; whereas, in a smaller study, there was a reported increase in MI but a decrease of unstable angina (16) . Several studies have shown that hsTnT assays have a higher sensitivity for acute MI compared with a conventional assay (4,10,11) as well as a better negative predictive value (11). The results from several studies have advocated that low-risk patients presenting with chest pain at the ED can be discharged safely with a rapid rule-out after the hsTnT assay results (17) alone or in combination with a risk score or algorithm as a tool for rule out (18) (19) (20) .
A large prospective multicenter cohort study by Body et al. also showed that patients with suspected Values are mean AE SD or n (%). *Diagnosis and/or prescriptions for drugs to treat the condition.
Abbreviations as in Table 1 . cardiac chest pain who have a negative hsTnT and no ischemia on electrocardiography could have a rapid rule-out, even without serial sampling. The incidence of 30-day MACE in these patients was 1.3%, which could be lowered to 1.1% by setting the cutoff at the limit of blank of the assay (3 ng/l) (17). Kelly et al. (21) conducted a small substudy of a prospective observational study and investigated the risk of MACE and revascularization within 30 days in patients without previously known coronary artery disease using troponin I. These patients were divided into different risk groups, and the "non-high-risk patients" were discharged directly from the ED. This subgroup had a very low risk of MACE: 0.4%, including revascularization (21).
Our results are within the range of estimations of both these studies. However, we report on discharged unselected patients, both previously healthy and with previous MI; moreover, the current study ASSAY USE AND OUTCOME AFTER ADMISSION FOR CHEST PAIN. In the current study, we observed that patients discharged after a short admission analyzed with hsTnT had more cardiovascular risk factors and a higher incidence of MACE within 30 days compared with patients analyzed with a conventional assay. Our (11) also found that hsTnT better identified patients at The association between evaluation with an hsTnT assay and major adverse cardiac event(s) (MACE) within 30 days of discharge from the emergency department with unspecified chest pain presented as crude odds ratios (ORs) with 95% confidence intervals (CIs). Abbreviation as in Figure 1 .
Nejatian et al. Risk profile and major adverse cardiac events (MACEs) were studied in patients discharged from the emergency department (ED) with unspecified chest pain at 16 different hospitals before and after the introduction of a high-sensitivity troponin T (hsTnT) assay. Directly discharged and patients discharged after admission were analyzed separately. Directly discharged patients had a lower risk profile and experienced fewer MACE when an hsTnT assay was in use, whereas the opposite was observed in patients discharged after admission.
The implementation of hsTnT assays in Swedish hospitals has improved evaluations at the ED.
Nejatian et al. or may be on the causal pathway to, the outcome, it was expected that the association between study period and outcome was weakened in the adjusted analysis.
CONCLUSIONS
This large registry-based study showed that the introduction of the hsTnT assay resulted in 0.3% (3 in 1,000) fewer adverse events in patients directly discharged from the ED with unspecified chest pain. On the contrary, the opposite was observed among these patients if they had been admitted. Our findings supported the idea that more true at-risk patients were identified and admitted. Considering the change in risk factor profiles for discharged and admitted patients with chest pain, together with the very small amount of missed cases in the current study, evaluation with the hsTnT assay appears to be of great help in the ED when deciding whether a patient can be sent home or not.
ADDRESS FOR CORRESPONDENCE: Dr. Atosa Nejatian, Karolinska University Hospital, Functional
